Dapiclermin

Drug Profile

Dapiclermin

Alternative Names: Axokine; Ciliary neurotrophic factor - Regeneron; pegAxokine; RG228

Latest Information Update: 03 Aug 2007

Price : $50

At a glance

  • Originator Regeneron Pharmaceuticals
  • Developer Emisphere Technologies; Regeneron Pharmaceuticals
  • Class Eye disorder therapies; Obesity therapies
  • Mechanism of Action Ciliary neurotrophic factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Huntington's disease; Obesity; Retinal disorders

Most Recent Events

  • 31 Dec 2006 Discontinued - Preclinical for Retinal disorders in USA (unspecified route)
  • 31 Dec 2006 Discontinued - Phase-III for Obesity in USA (SC)
  • 16 May 2006 No development reported - Preclinical for Retinal disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top